NCT00540436View on ClinicalTrials.gov

Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Hypertension, Pulmonary
Interventions
DRUG

GSK1325760A

Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.

Trial Locations (15)

470-1192

GSK Investigational Site, Aichi

830-0011

GSK Investigational Site, Fukuoka

060-8543

GSK Investigational Site, Hokkaido

060-8648

GSK Investigational Site, Hokkaido

920-8641

GSK Investigational Site, Ishikawa

228-8555

GSK Investigational Site, Kanagawa

606-8507

GSK Investigational Site, Kyoto

701-1192

GSK Investigational Site, Okayama

901-0243

GSK Investigational Site, Okinawa

565-8565

GSK Investigational Site, Osaka

431-3192

GSK Investigational Site, Shizuoka

113-8431

GSK Investigational Site, Tokyo

113-8655

GSK Investigational Site, Tokyo

143-8541

GSK Investigational Site, Tokyo

160-8582

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00540436 - Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter